# US 2026/0091147 A1 · Method for detecting innate immune action in vivo using gpr84-pet

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091147 A1
- Document ID: US20260091147A1
- Status: Published application
- Kind: A1
- Application number: 19/475,452
- Filed: 2024-04-17
- Published: 2026-04-02
- Earliest claimed: 2023-04-17
- Assignees: The Board of Trustees of the Leland Standford Junior University
- Applicants: The Board of Trustees of the Leland Standford Junior University
- Inventors: Michelle L. James; Isaac M. Jackson; Mausam Kalita; Sydney C. Nagy
- Web page: https://patentgrep.com/patent/US20260091147A1

## CPC

- A61K 51/0459: {having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine}
- C07B 59/002: {Heterocyclic compounds}
- A61B 6/037: {Emission tomography}
- A61K 51/0455: {having six-membered rings with one nitrogen as the only ring hetero atom}
- C07D 471/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K 2123/00: Preparations for testing in vivo
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

In one aspect, the disclosure relates to 11C and 18F radiolabeled compounds useful as positron emission tomography (PET) tracers for selective imaging of neuroinflammation associated with expression transmembrane protein GPR84, methods of making the same, and compositions comprising the same. In one aspect, the compounds can cross the blood brain barrier, have a high signal to noise ratio, a large dynamic range, and are highly specific for their targets. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

## Claims

### Claim 1

A radiolabeled compound having a structure of Formula I:
wherein X is N or CH;
wherein R1 and R2 are both hydrogen and the bond marked by * is a single bond, or wherein R1 and R2 are bridged to form a heteroaromatic ring and the bond marked by * is a component of the heteroaromatic ring;
wherein R3 comprises a halogen, C1-C4 alkyl ether, or fluorosulfonate group;
wherein R3 comprises at least one radioisotope; and
wherein R4 and R5 are independently hydrogen or methyl.

### Claim 2 (depends on 1)

The radiolabeled compound of claim 1, wherein the at least one radioisotope is selected from 11C and 18F.

### Claim 3 (depends on 1)

The radiolabeled compound of claim 1, wherein X is N.

### Claim 4 (depends on 1)

The radiolabeled compound of claim 1, wherein X is CH.

### Claim 5 (depends on 1)

The radiolabeled compound of claim 1, wherein R1 and R2 are both hydrogen and the bond marked by * is a single bond.

### Claim 6 (depends on 1)

The radiolabeled compound of claim 1, wherein the radiolabeled compound has the structure

### Claim at position 7

-10. (canceled)

### Claim 11 (depends on 1)

The radiolabeled compound of claim 1, wherein R3 is selected from

### Claim 12 (depends on 1)

The radiolabeled compound of claim 1, wherein the radiolabeled compound is selected from

### Claim 13 (depends on 1)

The radiolabeled compound of claim 1, wherein the radiolabeled compound undergoes beta plus decay and emits a positron.

### Claim at position 11

-15. (canceled)

### Claim 16 (depends on 1)

The radiolabeled compound of claim 1, wherein the radiolabeled compound is capable of penetrating an intact blood-brain barrier (BBB).

### Claim 17 (depends on 1)

A pharmaceutical composition comprising the radiolabeled compound of claim 1.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

A method for imaging inflammation in a subject, the method comprising:
(a) administering the radiolabeled compound of claim 1 to the subject; and
(b) performing positron emission tomography (PET) on the subject.

### Claim 20 (depends on 19)

The method of claim 19, wherein the inflammation is associated with increased GPR84 expression relative to a level of GPR84 expression in a subject not experiencing inflammation.

### Claim 21 (depends on 1)

The method of claim 1, wherein the inflammation comprises neuroinflammation, gut inflammation, or any combination thereof.

### Claim 22 (depends on 19)

The method of claim 19, wherein the radiolabeled compound binds to GPR84.

### Claim 23 (depends on 19)

The method of claim 19, wherein the subject is a mammal.

### Claim 24

(canceled)

### Claim 25 (depends on 1)

A method for determining a stage of a disease associated with increased GPR84 expression in a subject, the method comprising:
(a) administering the radiolabeled compound of claim 1 to the subject;
(b) performing a positron emission tomography (PET) scan on the subject; and
(c) comparing results of the PET scan to one or more standard PET scans.

### Claim 26

(canceled)

### Claim 27 (depends on 25)

The method of claim 25, wherein the disease comprises Alzheimer's disease, multiple sclerosis, glioblastoma, brain metastases, stroke, central nervous system (CNS) injury, a psychiatric disorder, multiple sclerosis, ulcerative colitis, another inflammatory bowel disease, atherosclerosis, pulmonary fibrosis, arthritis, neuropathic pain or other types of pain, chronic fatigue syndrome, fibromyalgia, a bacterial or viral infection, cancer, or any combination thereof.

### Claim 28 (depends on 1)

A method of monitoring immune response in a subject in response to a treatment for a disease associated with increased GPR84 expression, the method comprising:
(a) administering the radiolabeled compound of claim 1 to the subject;
(b) performing a positron emission tomography (PET) scan on the subject; and
(c) comparing results of the PET scan to results of an initial PET scan of the subject, wherein the initial PET scan was conducted prior to disease treatment or at an earlier stage of disease treatment.

### Claim 29

(canceled)

### Claim 30 (depends on 28)

The method of claim 28, wherein the disease comprises Alzheimer's disease, multiple sclerosis, glioblastoma, brain metastases, stroke, central nervous system (CNS) injury, a psychiatric disorder, multiple sclerosis, ulcerative colitis, another inflammatory bowel disease, atherosclerosis, pulmonary fibrosis, arthritis, neuropathic pain or other types of pain, chronic fatigue syndrome, fibromyalgia, a bacterial or viral infection, cancer, or any combination thereof.
